Elite in Prolymphocytic Leukemia

Jan Durig

St. Augustinus MVZ GmbH, 
Gelsenkirchen, NW, DE 
Elite in Prolymphocytic Leukemia
St. Augustinus MVZ GmbH, 
Gelsenkirchen, NW, DE 
OverviewLocationsClinical Research

Overview

Jan Durig practices in Gelsenkirchen, Germany. Durig is rated as an Elite expert by MediFind in the treatment of Prolymphocytic Leukemia. Their top areas of expertise are Prolymphocytic Leukemia, Chronic T-Cell Leukemia (CTCL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 105 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 10 articles in the study of Prolymphocytic Leukemia.

Locations

St. Augustinus MVZ GmbH, Gelsenkirchen, NW, Germany
Other Locations
St Josef Krankenhaus Werden, Essen, NW, Germany
Hamburg, HH, Germany
Heidelberg, BW 69120, Germany
Munich, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Enrollment Status: Active_not_recruiting
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Obinutuzumab
Study Phase: Phase 2
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
View 1 Less Clinical Trial

105 Total Publications

Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma.
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma.
Journal: Scientific reports
Published: March 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Durig's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile